NASDAQ:CHRS Coherus Oncology (CHRS) Stock Price, News & Analysis $1.61 +0.04 (+2.55%) Closing price 04:00 PM EasternExtended Trading$1.62 +0.00 (+0.31%) As of 07:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Coherus Oncology Stock (NASDAQ:CHRS) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Coherus Oncology alerts:Sign Up Key Stats Today's Range$1.59▼$1.6550-Day Range$1.48▼$1.9952-Week Range$0.71▼$2.62Volume919,158 shsAverage Volume1.87 million shsMarket Capitalization$248.34 millionP/E Ratio0.96Dividend YieldN/APrice Target$8.67Consensus RatingModerate Buy Company Overview Coherus Oncology, Inc. is a commercial-stage biopharmaceutical company focused on the development, manufacturing and commercialization of biologic therapies for oncology support and immuno-oncology. Founded in 2010 and headquartered in Redwood City, California, Coherus specializes in biosimilar versions of established oncology agents as well as novel immunotherapy candidates. The company’s lead marketed products include Udenyca (pegfilgrastim-cbqv) and Fulphila (pegfilgrastim-jmdb), biosimilars to Amgen’s Neulasta, which are designed to reduce the incidence of infection in patients undergoing myelosuppressive chemotherapy. These pegfilgrastim biosimilars have received approval from the U.S. Food and Drug Administration and are distributed through a network of specialty pharmacies and wholesalers, supporting patients in the United States and select international markets. Beyond supportive-care biologics, Coherus Oncology maintains a pipeline of immuno-oncology candidates, including anti-PD-1 and anti-CTLA-4 monoclonal antibodies in clinical development. The company’s research and development efforts are aimed at advancing therapies for melanoma, non-small cell lung cancer and other solid tumors, with partnerships and licensing agreements that extend its global reach and facilitate late-stage clinical trials across North America, Europe and Asia. Coherus operates its own manufacturing facilities to support both development and commercial supply, ensuring scalable production capabilities. Richard E. Fair serves as President and Chief Executive Officer, leading a management team with deep expertise in biologics development and oncology commercialization. Under this leadership, Coherus continues to expand its product portfolio and broaden patient access to high-quality oncology therapies.AI Generated. May Contain Errors. Read More Coherus Oncology Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks55th Percentile Overall ScoreCHRS MarketRank™: Coherus Oncology scored higher than 55% of companies evaluated by MarketBeat, and ranked 320th out of 858 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.8 / 5Analyst RatingModerate Buy Consensus RatingCoherus Oncology has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on no strong buy ratings, 3 buy ratings, 1 hold rating, and no sell ratings.Upside PotentialCoherus Oncology has a consensus price target of $8.67, representing about 438.3% upside from its current price of $1.61.Amount of Analyst CoverageCoherus Oncology has only been the subject of 2 research reports in the past 90 days.Read more about Coherus Oncology's stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Coherus Oncology are expected to grow in the coming year, from ($0.93) to ($0.91) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Coherus Oncology is 0.96, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 38.94.Price to Earnings Ratio vs. SectorThe P/E ratio of Coherus Oncology is 0.96, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 20.99.Price to Book Value per Share RatioCoherus Oncology has a P/B Ratio of 3.16. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Coherus Oncology's valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted19.62% of the float of Coherus Oncology has been sold short.Short Interest Ratio / Days to CoverCoherus Oncology has a short interest ratio ("days to cover") of 25.51, which indicates bearish sentiment.Change versus previous monthShort interest in Coherus Oncology has recently decreased by 0.55%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCoherus Oncology does not currently pay a dividend.Dividend GrowthCoherus Oncology does not have a long track record of dividend growth. News and Social Media1.3 / 5News SentimentN/A Search Interest18 people have searched for CHRS on MarketBeat in the last 30 days. This is an increase of 20% compared to the previous 30 days.MarketBeat Follows5 people have added Coherus Oncology to their MarketBeat watchlist in the last 30 days. Company Ownership1.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Coherus Oncology insiders have not sold or bought any company stock.Percentage Held by Insiders8.08% of the stock of Coherus Oncology is held by insiders.Percentage Held by Institutions72.82% of the stock of Coherus Oncology is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Coherus Oncology's insider trading history. Receive CHRS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Coherus Oncology and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CHRS Stock News HeadlinesCoherus Biosciences Signals Confident Oncology Earnings OutlookMay 14, 2026 | theglobeandmail.comWhat You Need To Know About The Coherus Oncology, Inc. (NASDAQ:CHRS) Analyst Downgrade TodayMay 14, 2026 | finance.yahoo.comYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time through a temporary download link. He plans to charge for it soon. Download your copy now and lock it in at no cost, regardless of future pricing.May 22 at 1:00 AM | Profits Run (Ad)Coherus Oncology (NASDAQ:CHRS) Research Coverage Started at GuggenheimMay 14, 2026 | americanbankingnews.comCoherus Oncology: Setting Up For Important Readouts In Mid-2026May 13, 2026 | seekingalpha.comCoherus Oncology, Inc.: Coherus Oncology Reports First Quarter 2026 Financial Results and Provides Business UpdateMay 12, 2026 | finanznachrichten.deGuggenheim initiates coverage of Coherus Oncology (CHRS) with buy recommendationMay 12, 2026 | msn.comCoherus Oncology, Inc. (CHRS) Q1 2026 Earnings Call TranscriptMay 12, 2026 | seekingalpha.comSee More Headlines CHRS Stock Analysis - Frequently Asked Questions How have CHRS shares performed this year? Coherus Oncology's stock was trading at $1.42 at the beginning of the year. Since then, CHRS shares have increased by 13.4% and is now trading at $1.61. How were Coherus Oncology's earnings last quarter? Coherus Oncology, Inc. (NASDAQ:CHRS) issued its earnings results on Monday, May, 11th. The biotechnology company reported ($0.25) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.26) by $0.01. The biotechnology company had revenue of $12.31 million for the quarter, compared to analysts' expectations of $14.22 million. Coherus Oncology had a net margin of 397.30% and a negative trailing twelve-month return on equity of 198.90%. Read the conference call transcript. Does Coherus Oncology have any subsidiaries? Coherus Oncology subsidiaries include these companies: InteKrin, Coherus Intermediate Corp, InteKrin Russia, and InteKrin Therapeutics Inc.. When did Coherus Oncology IPO? Coherus Oncology (CHRS) raised $85 million in an IPO on Thursday, November 6th 2014. The company issued 6,296,300 shares at a price of $12.00-$15.00 per share. Who are Coherus Oncology's major shareholders? Coherus Oncology's top institutional shareholders include Sei Investments Co. (0.29%), Renaissance Technologies LLC (0.22%), Bank of America Corp DE (0.21%) and Bank of New York Mellon Corp (0.18%). Insiders that own company stock include Dennis M Lanfear and Mats Wahlstrom. View institutional ownership trends. How do I buy shares of Coherus Oncology? Shares of CHRS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Coherus Oncology own? Based on aggregate information from My MarketBeat watchlists, some other companies that Coherus Oncology investors own include Voyager Therapeutics (VYGR), Waste Connections (WCN), American Water Works (AWK), DiamondRock Hospitality (DRH), The RMR Group (RMR), Humana (HUM) and AUO (AUOTY). Company Calendar Last Earnings5/11/2026Today5/22/2026Jefferies Global Healthcare Conference 20266/04/2026Next Earnings (Estimated)8/06/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (9m+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 CHRS's financial health is in the Green zone, according to TradeSmith. CHRS has been in this zone for over 9 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:CHRS CIK1512762 Webwww.coherus.com Phone(650) 649-3530FaxN/AEmployees330Year Founded2010Price Target and Rating Average Price Target for Coherus Oncology$8.67 High Price Target$12.00 Low Price Target$4.00 Potential Upside/Downside+438.3%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage4 Analysts Profitability EPS (Trailing Twelve Months)$1.67 Trailing P/E Ratio0.96 Forward P/E RatioN/A P/E GrowthN/ANet Income$168.02 million Net Margins397.30% Pretax Margin-368.28% Return on Equity-198.90% Return on Assets-46.65% Debt Debt-to-Equity Ratio0.47 Current Ratio1.56 Quick Ratio1.52 Sales & Book Value Annual Sales$46.88 million Price / Sales5.30 Cash FlowN/A Price / Cash FlowN/A Book Value$0.51 per share Price / Book3.16Miscellaneous Outstanding Shares154,250,000Free Float141,787,000Market Cap$248.34 million OptionableOptionable Beta1.01 Social Links 7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (NASDAQ:CHRS) was last updated on 5/22/2026 by MarketBeat.com Staff. From Our PartnersHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | SponsoredThe SpaceX supplier that shipped 5 billion chips to StarlinkWhen Nvidia surged 770%, its data center cooling supplier Vertiv climbed 1,700%. When Apple ran 2,000%, suppli...Weiss Ratings | Sponsored"Computers are about to become obsolete" - George Gilder. Here’s why.George Gilder predicted the iPhone 16 years early, called Netflix a decade before it dominated streaming, and ...Eagle Publishing | SponsoredYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...Profits Run | SponsoredSystem failure: The strongest leverage for gold…$9 trillion in U.S. debt must be refinanced in 2026 - at current rates - while the largest foreign buyers of T...Golden Portfolio | SponsoredA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...Porter & Company | SponsoredI was right about SpaceXJeff Brown predicted Bitcoin before it climbed as high as 52,400%, Tesla before 2,150%, and Nvidia before 32,0...Brownstone Research | SponsoredSpaceX just filed. The clock is ticking.Reuters reports Elon Musk filed secretly. Barron's says it's being finalized behind closed doors. CNBC just re...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Coherus Oncology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Coherus Oncology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
